Downregulation of miR-301a-3p sensitizes pancreatic cancer cells to gemcitabine treatment via PTEN.

Abstract

MiR-301a-3p confers resistance to gemcitabine by regulating the expression of PTEN. The co-delivery of miR-301a-3p and gemcitabine might be an effective therapeutic regimen for patients with pancreatic cancer.